The Role Of ～(131)I On Apoptosis Of Thyrocytes In Patient With Graves' Disease

Objectives: To investigate the changes of the apoptotic protein Fas FasL and the anti-apoptotic protein Bcl-2 of thyrocytes in the patients with Graves" disease before and 2 weeks after I administration and analyze the relativity between the dose of ¹³¹I treatment and the apoptosis-related protein we mentioned above, and to study the relationship between hypothyroidism due to radioiodine and the change of apoptosis-related protein pre-therapeutic and post-therapeutic.Methods: Thyroid tissue was obtained from 22 patients (F9, M13, mean age 35.2±8.67, 19-51 years) with Graves disease by histological biopsy before and after ' I treatment, and the biopsy sample were examined by immunohistochemical method for the expression of Fas, FasL and Bcl-2, using specific antibodies. Quantitative analysis was performed by Mias 2000 pathological image system. Than we detected the serum FT₃ FT₄ and sTSH concentration using RIA before therapy and at the 3^rd month after treatment, respectively. According to the serum concentration of FT₃, FT₄ and sTSH, all pts were divided into two groups: hypothyroid (G1) and non-hypothyroid (G2). for Gl, the serum FT₃, FT₄ were lower than normal and sTSH were higher than normal; For G2, the serum FT₃, FT₄ and sTSH were normal or FT₃, FT₄ were higher than normal and sTSH were lower than normal. The statistical analyses included t-test and linear correlation.Results: 1. The positive staining of Fas FasL and Bcl-2 were detected in thyrocytes from patient with GD irrespective pre-therapeutic and post-therapeutic. The PU of Fas in thyrocytes before and after treatment were 12.93±1.80, 23.43±6.60 respectively, there was statistical difference between them (P<0.02). FasL in thyrocytes before and after treatment were 14.56±4.06, 20.4±6.46 respectively, P <0.002. Bcl-2 in thyrocytes before and after treatment were 115.22+ 5.94, 21.68 ±7.83 respectively, P<0.005.2. A statistically significant correlation was found between the dose of ¹³¹I treatment and the PU value of apoptotic protein Fas FasL (r_Fas=0.79, r_FasL=0.76), in contrast, for anti-apoptotic protein Bcl-2, there was no a statistically significant correlation (r_Bcl-2=0).3. For G1: the PU of Fas in thyrocytes before and after treatment were 17.82 ± 9.18, 29.17±9.76 respectively, there was statistical difference between them (P<0.05), the same FasL: 17.82 ± 9.18, 29.17±9.76, P<0.05, but the PU value of Bcl-2 in thyrocytes before and after treatment were 16.85±7.06, 21.39 ± 10.41, there was no statistical difference between them (P>0.05). For G2: the PU of Fas in thyrocytes before and after treatment were 16.20 ± 6.05, 18.10 ± 3.89...